ArticleBMC health services research2026

An updated cost-effectiveness analysis of osimertinib versus placebo in resected EGFR-mutated non-small cell lung cancer: the perspective of the United States.

Fangping Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.